Yogeshwar Bachhav is a pharmacist by training and has PhD in
advanced drug-delivery systems from ICT, Mumbai (India). He has around 16 years of post-PhD experience in Europe in the field of pharmaceutical development of investigational drugs. He has contributed to the success of the clinical candidates ranging from preclinical to phase 1, 2, and 3 trials followed by commercial launch. Yogesh has worked as a Research Scientist for around four years on a collaborative project between Pantec Biosolutions AG (Lichtenstein) and University of Geneva, Switzerland. After this, he has worked as a Formulation Manager at Debiopharm Group, Lausanne, Switzerland, for around four years in the capacity of a lab head, where he successfully developed preclinical and clinical formulations for oncology indication. Currently Yogesh is working as a Associate Director (Consultant) at AiCuris Anti-infective Cures AG Germany and responsible for pharmaceutical development of investigational drugs in the domain of innovative anti-viral and anti-bacterial drugs.
Yogesh’s expertise in the field of advanced drug-delivery system comprises pre-formulation, formulation development of small molecules and/or peptides
for oral, dermal, and parenteral applications. Also, he has exposure to in-house development and outsourcing these novel dosage forms.
Besides several publications in the targeted formulation field, Yogesh is a well-known expert with over 30 conference proceedings and has been named Wiley-VCH in the same book series titled Innovative Dosage Forms: Design and Development at Early Stage. He is also serving as visiting faculty at reputed Pharmacy Schools in India.

Presentation Title: Feasibility of Developing Topical Formulation: Concept to Advanced Clinical Phase

Abstract: The topical route of administration, a crucial aspect in drug development, remains attractive to avoid unwarranted systemic exposure of the drugs. The development of a topical formulation for an investigational compound is a distinct challenge compared to other routes of administration, linked to the drug's physicochemical properties and dose. This topic is of significant importance and will be explored in detail in the upcoming presentation.

In his presentation at BOS Manchester 2024, Dr. Yogeshwar Bachhav, a seasoned Director and Consultant at AiCuris Anti-infective Cures AG, Germany, will highlight the challenges linked to developing a topical formulation of a poorly soluble compound, especially the transition from the concept stage formulation to advanced clinical stage drug product and meeting regulatory expectations. The talk will also underscore the criteria for selecting a CDMO partner to develop a topical formulation, providing audience with expert insights to guide the decisions.

View company profile